LIMITED SOURCE JUSTIFICATION •1. Defense Logistics Agency (DLA) Troop Support, Medical Supply Chain, is the contracting activity. •2. The action submitted for approval covers the purchase 596 Packages of Baxter Healthcare Corp's, PRALIDOXIME CHLORIDE, STERILE, NDC 60977-0141-01, NSN 6505-01-080-1986 for Camp Lejeune, NC. •3. The required item is available on Baxter's Federal Supply Schedule (FSS) contract V797P-5032B which expires on 14 July 2014. The total estimated dollar value is $213,403.76. •4. The authority waiving competition requirements is FAR 8.405-6(a)(1)(i)(B), as the following circumstance in FAR 16.505(b)(2)(ii) applies: only one source is capable of providing the supplies or services required at the level of quality required because the supplies or services ordered are highly specialized. •5. After extensive market research, both through the internet and on GSA Advantage, it was determined that there was only one FDA approved manufacturer and FSS holder for this item. •6. Pursuant to FAR 8.404(d), the Department of Veterans Affairs (DVA) has already determined the FSS price for the items covered under the FSS contract on this order to be fair and reasonable . Prices under this order will reflect a 1% discount from the FSS price. This acquisition represents the best value for the Government and will result in the lowest overall cost alternative to meet the Government's needs. •7. In accordance with DLAD 7.9002, this order is in the best interest of DLA, considering such factors as satisfying customer requirements; cost effectiveness (taking into account discounts and fees) and price; delivery schedule; non-availability of a suitable contract within DOD; contract administration/oversight; small business opportunities; and all other factors, as applicable. •8. The Defense Logistics Agency is in constant support of the Medical industry developing new and maintaining existing Drugs. DLA Troop Support will continue to perform market research and stay in contact with the FDA to garner any information on introduction of new drugs into the marketplace that would be comparable to this one. The applicable specification for this item is not considered restrictive and the lack of additional manufacturers is a result of market conditions for this type drug and not due to any Government imposed restrictions. This is the best price available for this item. Funding is available and appropriate for the acquisition. •9. As the Contracting Officer, I hereby certify that this justification is accurate and complete to the best of my knowledge and belief.